EPS of $1.19 for the same period compares with $1.04 a year ago ... The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Haemonetics. Also, the stock has ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果